PVP K17, K25, K30, and K90 are supplied as linear 1-vinyl-2-pyrrolidone homopolymers meeting Ph. Eur. 0685, USP-NF Povidone, and JP Povidone. The K suffix denotes the nominal Fikentscher K value derived from relative viscosity of a 1.0% w/w aqueous solution at 25°C using an Ubbelohde capillary viscometer; the pharmacopoeial acceptance range is 85.0–115.0% of the stated K value. The four grades are not interchangeable in formulation because the K value governs weight-average molecular weight, aqueous solution viscosity, binder film strength, and route-specific acceptability. The product is a white to cream-white hygroscopic powder with controlled pH 3.0–5.0 in a 5.0% w/w aqueous solution, water content not more than 5.0%, sulfated ash not more than 0.1%, and nitrogen content 11.5–12.8% on the anhydrous basis. Residual aldehydes and peroxides are controlled because peroxides above 400 ppm can oxidize actives such as catecholamines, phenothiazines, and peptides. The material is hygroscopic, and exposure above 60% relative humidity increases moisture uptake and sticking during compression.

Across the four grades, the relationship between K value and aqueous viscosity is nonlinear; at equal concentration, K90 produces a thickening effect more than an order of magnitude greater than K30. This dictates the choice of granulation equipment and binder concentration.

In production-scale wet granulation, the polymer is delivered as an aqueous or aqueous-alcoholic solution through a two-fluid nozzle. A K30 solution at 5.0% w/w can be sprayed on a top-spray fluid-bed granulator with a 1.2 mm nozzle and atomization air pressure 0.8–1.5 bar; the same equipment requires dilution to 1.0–2.0% w/w for K90 to avoid droplet sizes above 50 µm and binder-rich agglomerates. High-shear mixers with bowl volumes of 25–600 L and impeller tip speeds of 4–8 m/s are used for K30 wet massing; for K90, impeller torque may rise by 20–40% at the same binder volume fraction because of the higher wet-mass consistency. Drying after K30 granulation is typically conducted in a fluid bed at inlet air temperature 55–65°C and product temperature 28–32°C until loss on drying is below 2.0%. K90 granules require longer drying or lower inlet temperature to avoid surface crusting. Dried granules are milled through 1.0–1.5 mm screens; the fraction retained above 850 µm should be below 20% for tablet compression.

When K90 Replaces K30 in Aqueous Granulation: Viscosity Thresholds and Torque Rise

Substitution of K90 for K30 at equal concentration is not a drop-in change. In a 5.0% w/w aqueous solution, K30 exhibits 5.5–8.5 mPa·s at 25°C, while K90 can exhibit 300–700 mPa·s; the resulting binder droplet size increases and the wet mass approaches a cohesive paste at lower liquid addition. On a 16-station rotary tablet press operating at 30–50 rpm, granules made with K90 at 3.0% binder concentration may show hardness 80–140 N but also capping and lamination if residual moisture is below 1.5% or above 3.0%. In USP <711> dissolution testing at 50 rpm paddle speed, a K90-containing immediate-release formulation can slow drug release; if the dissolution specification is Q=80% at 30 min, the formula may fail unless disintegrant level is increased by 1.0–2.0%. For extended-release matrices, K90 at 5.0–10.0% w/w can act as a binder and gel-former, but it is usually combined with hypromellose or polyethylene oxide rather than used alone because povidone erosion is too rapid in aqueous media to control release over 12–24 h.

Povidone K17 is the lowest molecular weight grade with typical weight-average molecular weight 7,000–11,000 g/mol and 10% w/w aqueous viscosity 2–3 mPa·s. Because renal clearance of povidone is molecular-weight-dependent, K17 is the grade normally referenced for injectable and ophthalmic formulations; K90 is not considered suitable for parenteral administration in most regulatory jurisdictions. In lyophilized vials, K17 can act as a crystallization inhibitor and bulking excipient at 1.0–5.0% w/v, but it does not replace trehalose or sucrose as a lyoprotectant and may depress the collapse temperature in systems with low glass transition temperature. Sterilizing filtration through 0.22 µm polyethersulfone membranes is feasible for K17 solutions at 5.0% w/v, but K90 at levels above 2.0% w/v can cause flux decay and membrane polarization at 20–25°C. Peroxide and aldehyde content must be reviewed lot-by-lot for injectable use; a limit of not more than 400 ppm peroxides is applied by several manufacturers, although published data for specific parenteral drug products is limited and formulators should verify through drug master files.

What Limits Direct-Compression Binder Performance for K25 and K30?

For direct compression and dry granulation, K25 and K30 are used at 2.0–5.0% w/w as dry binders. Their compaction mechanism under 15–25 kN compression force is primarily plastic deformation and hydrogen bonding with excipient surfaces; their binding efficiency is lower than that of microcrystalline cellulose but sufficient for low-dose tablets. The spray-dried morphology with particle D50 between 50–150 µm improves flow when blended with lactose monohydrate D50 100–150 µm; however, hygroscopicity at 60% relative humidity causes moisture uptake and sticking on rotary tablet presses. Preconditioning at 40–50°C and 20–30% relative humidity for 2–4 h is advised before direct compression. In capsule granulation, a K25 solution at 3.0% w/w sprayed onto a mannitol-starch blend in a fluid-bed granulator with inlet air 55–65°C and product temperature 28–32°C yields granules with fines below 75 µm controlled below 20% to maintain fill weight uniformity. K30 at the same concentration produces harder granules and may slow capsule dissolution if the gelatin or hypromellose shell does not disintegrate rapidly.

The compendial release matrix for the four grades is summarized below.

Grade substitution in an approved oral solid dosage form triggers comparative dissolution testing under USP <711> or Ph. Eur. 2.9.3 and may require a post-approval change under FDA SUPAC-IR or EMA variation guidelines. A change from K30 to K90 in an immediate-release tablet can alter the hydrated diffusion layer and reduce the dissolution rate; formulators use an f2 similarity factor of 50–100 over 12 time points to demonstrate equivalence. Povidone is listed in the FDA Inactive Ingredient Database for oral, topical, and parenteral routes, with route-specific maximum potency values; the injectable grade must meet bacterial endotoxin and particulate requirements under USP <85> and USP <788>. For oral dosage forms, particle size and bulk density are controlled to ensure weight variation below 5.0% on 10-station encapsulators and tablet presses.

Differences Between Linear Povidone, Crospovidone, and Copovidone in Oral Solid Dose Processes

Linear povidone K25/K30 is water-soluble and functions primarily as a wet binder; crospovidone is an insoluble crosslinked homopolymer that functions as a superdisintegrant by wicking and swelling at 2.0–5.0% w/w without forming a viscous diffusion barrier. Replacing linear povidone with crospovidone at the same percentage reduces binder capacity and may lower tablet hardness below 60 N unless compensated with a dry binder such as copovidone. Copovidone, a vinylpyrrolidone-vinyl acetate copolymer, has a glass transition temperature near 106°C, which is lower than the 150–175°C reported for high-molecular-weight povidone; this makes copovidone more suitable for hot-melt extrusion in twin-screw extruders with L/D 25–40 and zone temperatures 120–160°C. Povidone K90 is distinguished by the highest solution viscosity and film tensile strength; in film-coating applications it is used at 2.0–4.0% w/w in low-solids coating dispersions below 10% total solids to avoid nozzle blockage. Povidone K17 differs from K25/K30/K90 by its low solution viscosity and lower binding strength; it is selected when minimal impact on disintegration and dissolution is required, or when a parenteral grade is indicated.

Because the polymer is hygroscopic, storage at 15–25°C in sealed HDPE drums with desiccant is required when ambient relative humidity exceeds 60%; open bags on the production floor can exceed 5.0% moisture within 8–12 h in humid environments, causing bridging in roller compactors and picking on tablet tooling. Povidone is incompatible with strong oxidizing agents and can complex with polyphenols and proteins via hydrogen bonding; preformulation screens should include a binary compatibility study at 40°C/75% RH for 4–12 weeks according to ICH Q1A(R2). The powder should not be combined with strong acids or bases in hot aqueous stock solutions because the pyrrolidone ring can hydrolyse, increasing residual 2-pyrrolidone. For oral liquids, K25 and K30 at 2.0–5.0% w/v act as viscosity modifiers and crystallization inhibitors for weak acids; however, high concentrations of divalent cations can cause salt precipitation or cloud point changes. Because residual peroxide levels are stability-critical, peroxide value by Ph. Eur. 2.5.5 or equivalent should be included in release and stability protocols.